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Flow-induced neointimal regression in baboon
polytetrafluoroethylene grafts is associated with
decreased cell proliferation and increased apoptosis
Scott A. Berceli, MD, PhD,a Mark G. Davies, MD, PhD, FRCSI,b Richard D. Kenagy, PhD,c and
Alexander W. Clowes, MD,c Seattle, Wash
Objective: We have previously shown that baboon grafts subjected to elevated shear stress exhibit an increase in luminal
area through atrophy of the neointimal layer. This study was designed to investigate the smooth muscle cell (SMC)
growth kinetics during early regression and evaluate the influence of nitric oxide (NO) in the regulation of this process.
Methods: Sixteen baboons underwent bilateral polytetrafluorethylene aortoiliac graft placement. After development of a
neointima over an 8-week period, blood flow through one graft was increased with placement of a downstream
arteriovenous fistula. Grafts were harvested at 4 (n  6), 7 (n  5), and 14 (n  5) days and assessed for neointimal
cross-sectional area, SMC proliferation and apoptosis, and macrophage infiltration. High-flow grafts were compared with
contralateral normal-flow controls. Eleven baboons underwent an identical experimental preparation to evaluate the
effect of NO inhibition. Eight weeks after graft implantation, the animals were treated with an initial bolus (100 mg/kg)
followed by continuous infusion (60 mg/kg/d) of either NG-nitro-L-arginine methyl ester (L-NAME; n  6) or the
inactive stereoisomer NG-nitro-D-arginine methyl ester (n  5). Grafts were harvested at 7 days and evaluated with the
experimental endpoints detailed previously.
Results: Distal fistula placement resulted in a 3.8-fold increase in mean centerline velocity and wall shear stress. Grafts
harvested during the initial 14 days after flow manipulation showed a progressive reduction in neointimal cross-sectional
area. This change was associated with a decrease in subendothelial SMC proliferation and an increase in neointimal SMC
apoptosis, the latter being in the region adjacent to the graft. Animals treated with L-NAME showed a 20% reduction in
platelet cyclic guanosine monophosphate and a 17% reduction in serum nitrate/nitrite concentrations. Despite this
inhibition of NO production, no effect on the flow-dependent changes in neointimal area, cell proliferation, or apoptosis
was observed in the L-NAME–treated baboons.
Conclusion: The local hemodynamic environment within healing prosthetic grafts modulates neointimal SMC prolifer-
ation and apoptosis. An increase in graft flow leads to atrophy of the neointima. (J Vasc Surg 2002;36:1248-55.)
In normal arteries, acute changes in blood flow induce
a change in lumen diameter, a process that is dependent on
the endothelium and may be an attempt to normalize shear
stress.1-3 In arteries where the geometry is constrained by
calcification associated with progression of atherosclerosis
or by an intraluminal stent, the vessels cannot contract or
relax in response to changes in blood flow. Instead, luminal
dimensions are altered only by changes in cell number and
the amount of extracellular matrix in the wall.4,5 The
hemodynamic environment regulates the healing of pros-
thetic grafts placed in the arterial circulation. In response to
an acute decrease in flow, polytetrafluorethylene grafts
placed in the aortoiliac position of baboons show a reduc-
tion in luminal cross-sectional area because of neointimal
thickening.6,7 This increase in neointimal mass is the result
of increased cell proliferation and synthesis of extracellular
matrix. Conversely, grafts subjected to elevated shearing
forces show an increase in lumen area through atrophy of
the neointimal layer by undefined mechanisms.8
In the neonatal circulation, arterial development or
atrophy is governed by the balance between cell prolifera-
tion and matrix protein synthesis on the one hand and cell
death and matrix degradation on the other.9-11 The local
hemodynamic environment modulates these opposing pro-
cesses by directly regulating the kinetics of tissue accumu-
lation in these immature arteries. In this study, we exam-
ined whether flow-induced neointimal regression in
prosthetic grafts occurs via a similar pertubation in this
balance. We show that this atrophy is associated with a
reduction in neointimal cell proliferation and an increase in
cell apoptosis. On the basis of an established role of nitric
oxide (NO) in the regulation of smooth muscle cell (SMC)
growth kinetics12-14 and our previous work showing in-
creased expression of endothelial NO synthase in response
to increased graft flows,8 we tested the hypothesis that NO
mediates atrophy in this situation of a constrained vascular
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geometry with the NO synthase (NOS) inhibitor, NG-
nitro-L-arginine methyl ester (L-NAME).15
MATERIALS AND METHODS
Experimental model. Sixteen male baboons (Papio
cynocephalus) weighing approximately 10 kg were used.
Bilateral aortoiliac polytetrafluorethylene grafts (5 cm
length, 4 mm diameter, 60 m internodal distance; W. L.
Gore, Newark, Del) were placed as previously described.6
Animals were anesthetized with ketamine hydrochloride
(10 mg/kg, intramuscularly) and maintained on isoflurane
inhalation anesthetic during all the operative procedures.
After 8 weeks, a superficial femoral artery to vein fistula (10
mm length) was created on one side to increase blood flow.
The contralateral graft was maintained as a normal flow
control.
Specimens were collected 4, 7, and 14 days after fistula
placement. At 17, 9, and 1 hour before necropsy, animals
were administered 5-bromo-2deoxyuridine (BrdU; 30
mg/kg/dose, intramuscularly). Animals were killed with
sodium pentobarbital (160 mg/kg, intravenously). Proxi-
mal aorta, graft, and external iliac artery specimens were
harvested en bloc, and representative samples were either
frozen or immersion fixed in 10% buffered formalin. Ani-
mal care and handling complied with the Guide for the
Care and Use of Laboratory Animals issued by the Institute
of Laboratory Animal Resources, Commission on Life Sci-
ences, National Research Council.
Hemodynamic monitoring. Duplex ultrasonogra-
phy was used to measure center-stream velocities and diam-
eter in the mid portion of each graft. Measurements were
performed 24 hours before placement of the distal fistula
and graft harvest. A time-averaged velocity for each graft
scan was determined through graphic integration of the
velocity waveforms over five cardiac cycles. Shear stress was
calculated with the Hagen-Poiseuille equation,   2 
  vtav/r; where  is the mean wall shear stress,  is the
viscosity of blood (0.035 poise), vtav is the time-averaged
centerline velocity, and r is the graft radius.
Histology. Formalin-fixed tissue segments were em-
bedded in paraffin, and histologic cross sections were
stained with hematoxylin/eosin. Digitized images were
collected and analyzed to determine luminal and neointi-
mal cross-sectional areas for each specimen. Mean areas
were obtained through averaging the results from two
mid-graft segments.
Immunohistochemical procedures were performed
with the avidin-biotin-peroxidase method (Vector Labora-
tories, Burlingame, Calif). Proliferating cells in the neoin-
tima were evaluated with an antibody to the thymidine
analogue BrdU (Boehringer-Mannheim, Basil, Switzer-
land).16 Detection of apoptotic cell death was evaluated
with in situ terminal deoxy nucleotidyl transferase-medi-
ated deoxy-uridine-triphosphate nick end labeling of frag-
mented DNA (TUNEL, Boehringer-Mannheim).17 Sec-
tions were counterstained with hematoxylin to assist in the
quantification of total nuclear density. Cells undergoing
apoptosis were also identified in frozen tissue sections with
an anti-active caspase-3 polyclonal antibody (PharMingen,
San Diego, Calif).18 Macrophage content within the neo-
intima was evaluated with HAM56 (Enzo, Farmingdale,
NY).
BrdU-stained, TUNEL-stained, and total nuclei were
manually counted in four regions per graft. Regions for
analysis were chosen from two separate mid-graft speci-
mens, located 1.5 cm from either the proximal or distal
anastomosis, respectively. Two regions of each graft speci-
men oriented at 0 degrees and 180 degrees around the
circumference of the wall were analyzed. To evaluate the
radial variation in BrdU and TUNEL staining within the
neointima, each region (200 m in width) was analyzed
throughout the thickness of the neointima. Neointimal
thicknesses ranged from 190 m to 980 m. On average,
3353 nuclei (with a mean of 117 BrdU positive and 265
TUNEL positive cells) over an area of 1.35 mm2 were
examined for each graft. These data served as input to
determine an average BrdU or TUNEL labeling index,
expressed as the ratio of stained to total nuclei, for each
graft.
To evaluate and analyze the radial variations in staining,
BrdU, TUNEL, and total nuclear concentration profiles of
varying thickness were mathematically transformed to a
fixed coordinate system. Within this scheme, the luminal
surface was assigned a depth of 0, the neointimal-graft
interface was assigned a depth of 1.0, and nuclear counts
were converted to 10 data points equally spaced along the
depth of the neointima. Normalized profiles were then
pooled to obtain group-averaged profiles for each experi-
mental condition.
All data are expressed as the mean the standard error
of the mean. Statistical differences in mean graft velocity
and wall shear stress were calculated with a paired Student t
test. Differences in neointimal thickness and global BrdU
and TUNEL staining were evaluated with two-way re-
peated measures analysis of variance with a Tukey post hoc
analysis (Sigma Stat, San Rafael, Calif). Differences in stan-
dardized BrdU and TUNEL profiles were assessed individ-
ually at each time point with a two-way analysis of variance
(Sigma Stat). P values of less than .05 were considered
significant.
NOS inhibition experiments. Bilateral aortoiliac
polytetrafluorethylene bypass grafts were placed in 11 male
baboons. After 8 weeks, a unilateral increase in flow was
induced with placement of a femoral arteriovenous fistula.
One hour before fistula placement, the NOS inhibitor,
L-NAME (Sigma, St Louis, Mo), was infused intravenously
at a dose of 100 mg/kg over 10 minutes. L-NAME (60
mg/kg/d) was administered continuously for the remain-
der of the experiment (7 days) with the intraperitoneal
placement of osmotic pumps (Alzet Model 2ML1, Cuper-
tino, Calif). The continuous L-NAME infusion rate was
selected on the basis of initial experiments showing that a
dose of 60 mg/kg/d reduced platelet cyclic guanosine
monophosphate (cGMP) levels (50% reduction from
baseline). Similar doses of L-NAME have produced phar-
macologic effects in other animal species (rat 10 to 50
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mg/kg/d,19-21 rabbit 2 to 12 mg/kg/d,22,23 pig 40 mg/
kg/d24). The initial 100 mg/kg loading dose was deter-
mined with a single-compartment pharmacokinetic model
of L-NAME metabolism, assuming a serum half life of 20.7
hours, volume of distribution of 1.76 L/kg, and a clearance
rate of 1.57 L/kg/d.25-27 Equal doses of the inactive
stereoisomer NG-nitro-D-arginine methyl ester (D-
NAME; Sigma) were administered in control animals.
Blood pressure and heart rate were noninvasively mon-
itored during the initial administration of L-NAME and
every other day for the remainder of the experiment. Blood
samples were collected before drug infusion and at 3 and 7
days after fistula placement. These specimens served to
monitor the biologic effect of the administered L-NAME
with an enzyme immunoassay (Amersham Pharmacia Bio-
tech, Piscataway, NJ) to measure cGMP levels in platelets28
and a Griess reagent-based colorimetric assay (Cayman
Chemical, Ann Arbor, Mich) to measure nitrate/nitrite
levels in serum.29
Seven days after fistula placement, animals were killed
and the grafts retrieved. BrdU (30 mg/kg/dose) was ad-
ministered at 17, 9, and 1 hour before graft harvest. Assess-
ment of neointimal cross-sectional areas, BrdU, and
TUNEL staining in graft specimens was performed as
described previously.
RESULTS
Hemodynamic parameters. Creation of the femoral
arteriovenous fistula resulted in an approximate four-fold
increase in mean centerline velocity within the graft, with a
corresponding increase in fluid shear stress at the neointi-
mal surface (Table I). Accompanying these changes was a
modest but statistically significant (P 	 .01) reduction in
blood velocity within the contralateral graft.
Morphometry. A progressive reduction in graft neo-
intimal areas was observed over the 14-day period in re-
sponse to elevated flow rates (Table II). This result con-
firmed our previous observation, which showed significant
neointimal atrophy after an 8-week exposure to increased
flows.8
BrdU and TUNEL staining. High-flow grafts
showed a decrease in BrdU labeling at day 4, and the
reductions observed at days 7 and 14 did not reach statis-
tical significance (Fig 1, A). This was accompanied by a
significant increase in TUNEL labeling, which persisted
above baseline levels at all time points examined (Fig 1 , B).
Average nuclear density was relatively independent of the
imposed hemodynamics throughout the regression period
(Fig 1 , C).
Both BrdU and TUNEL staining were localized to
specific regions within the graft neointima (Fig 2). Prolif-
erating neointimal cells were located near the lumen of the
graft, and apoptotic cells were present in the juxtagraft
region, deep within the neointima (Fig 3). Nuclear density
was elevated in the subendothelial region, reaching a min-
imum in the juxtagraft portion of the neointima. Immuno-
staining for activated caspase 3 confirmed apoptosis to be
the mechanism of cell death within this juxtagraft region
(Fig 2 , C).
Because macrophage factors might contribute to SMC
apoptosis, we counted the number of monocyte/macro-
phages in the neointima with HAM56 as a marker. The
number of macrophages was small and was not altered by
increasing flow (0.03 0.02% and 0.05 0.02% for day 4
normal and high flow, respectively; 0.04  0.0.2% and
0.05 0.03% for day 7 normal and high flow, respectively;
and 0.10 0.06% and 0.05 0.02% for day 14 normal and
high flow, respectively; mean  the standard error of the
mean as a percentage of the number of SMC).
Examination of external iliac arteries, distant to the
distal graft anastomosis and exposed to normal flow condi-
tions, showed only rare BrdU positive nuclei (	0.5%) and
an absence of TUNEL positive nuclei (data not shown).
Increases in iliac artery flow rates, induced by the distal
fistula, did not alter these staining patterns.
NOS inhibition experiments. Six animals under-
went treatment with L-NAME and five control animals
underwent treatment with D-NAME before placement of
the femoral fistula. After the initial infusion of L-NAME, a
significant increase in mean arterial pressure was observed
(before infusion, 72  3 mm Hg; after infusion, 100  9
mm Hg; P .016). No change in pressure was noted after
D-NAME administration (before infusion, 69 6 mm Hg;
after infusion, 72  3 mm Hg; P  not significant). This
increase in blood pressure was only transient. The mean
arterial pressures returned to baseline by day 2 and re-
mained at baseline through the completion of the 7-day
Table I. Hemodynamic changes in response to unilateral
fistula placement
Before fistula After fistula
Control-
side
graft
Fistula-
side
graft
Control-
side
graft
Fistula-
side
graft
Mean centerline velocity
(cm/s)
43  5 43  5 29  3 112  9
Shear stress
(dynes/cm2)
15  2 15  2 10  1 39  3
Control-side graft: before versus after fistula, P 	 .01.
Fistula-side graft: before versus after fistula, P 	 .0001.
Values are mean  standard error of mean.
Table II. Neointimal areas 4, 7, and 14 days after
unilateral fistula placement
Neointimal area (mm2)
Ratio high to
normal flow P valueNormal flow High flow
Day 4 (n  6) 4.3  0.3 3.8  0.1 0.87  0.06 NS
Day 7 (n  5) 4.8  0.1 3.9  0.1 0.80  0.05 .02
Day 14 (n  5) 4.8  0.1 3.2  0.1 0.67  0.05 	.001
Two-way analysis of variance: effect of flow (P 	 .001).
Values are mean  standard error of mean.
NS, Not significant.
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experiment. Blood velocity and shear stress changes after
fistula placement were not significantly different in the
L-NAME and D-NAME groups (Table III).
In agreement with our earlier observations, increased
graft flow resulted in a significant reduction in neointimal
cross-sectional area (Table IV). Administration of
L-NAME, however, did not prevent the flow-induced
change in neointimal area. An effect of the elevated graft
flow rate was also observed in the BrdU and TUNEL
labeling indices. High-flow grafts showed a significant re-
duction in cell proliferation and a trend towards an increase
in cell death. Neither the BrdU nor TUNEL index was
influenced by the infusion of L-NAME.
The animals administered L-NAME showed a signifi-
cant reduction in platelet cGMP concentrations (before
infusion, 4.1  0.2  10
9 pmole/platelet; after infusion,
3.3  0.7  10
9 pmole/platelet; P 	 .005), and the
animals receiving D-NAME showed no difference (before
infusion, 2.6  0.4  10
9 pmole/platelet; after infusion,
2.3  0.5  10
9 pmole/platelet; P  not significant). In
animals receiving L-NAME, a significant reduction in the
concentration of inactive NO end products, NO2 and NO3,
within the serum was observed (before infusion, 25.5 1.5
mmol/L; after infusion, 21.2  1.2 mmol/L; P  .05).
Serum NOx concentrations were unaffected by D-NAME
administration (before infusion, 25.4 2.8 mmol/L; after
infusion, 24.7  1.4 mmol/L; P  not significant).
DISCUSSION
We have shown that prosthetic grafts heal and that the
neointima grows in a normal flow environment largely
because of subendothelial SMC replication. Our findings
support the hypothesis that the rate at which neointimal
hyperplasia develops is dependent on the relative balance
between subendothelial cell replication and cell death in the
region adjacent to the graft. Through modulation of the
hemodynamic environment, and more specifically through
changes in shearing forces, the balance between these pro-
cesses appears to be altered and result in a change in
neointimal thickness within the graft. Regression within
our model occurs via simultaneous reduction in cell num-
ber and loss of surrounding matrix, as supported by the
stable cell density throughout the 2-week period. This
agrees with our recent findings that reveal an increase in
matrix metalloproteinases (MMP; MMP-2 and MMP-9)
under conditions of elevated flow.30
Our findings are similar to observations made in devel-
oping arteries, where cell proliferation and death are closely
regulated by fluid shear.10 This study is the first documen-
tation of the importance of this balance in vascular graft
healing. A similar inverse relationship between neointimal
thickness and shear stress has been observed in healing
stented human coronary arteries.5
Smooth muscle cell apoptosis has been identified as a
prominent feature in both primary atherosclerotic31 and
restenotic arterial lesions.32,33 Examination of these lesions
show the frequent colocalization of macrophages with ap-
optotic SMCs, and recent studies suggest that upregulation
of proinflammatory chemokines during programmed cell
death may be the underlying mechanism for this associa-
tion.34 Although baseline apoptosis in healing prosthetic
grafts proceeded in the relative absence of surrounding
macrophages and enhancement of cell death after increas-
ing fluid shear occurred without a change in macrophage
content, it is interesting that apoptosis was confined to the
neointima adjacent to the macrophage-rich graft matrix.
Further studies are needed to determine whether the local-
ization of apoptotic SMCs is the result of a gradient of
Fig 1. Neointimal SMC proliferation (BrdU labeling index; A), apoptosis (TUNEL labeling index; B), and nuclear
density (C) in normal-flow and high-flow grafts after fistula placement. Values are mean  standard error of mean.
*P 	 .05, normal-flow versus high-flow graft.
#P 	 .001, normal-flow versus high-flow graft.
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proapoptotic cytokines secreted by macrophages in the
graft matrix.
Our model permits us to evaluate the divergent
adaptive responses in prosthetic grafts and normal iliac
arteries that occur in response to changes in flow. In
agreement with previous observations, SMC prolifera-
tion and death in iliac arteries exposed to normal flow
were barely detectable.9 After an acute increase in flow,
wall shear within these arteries is normalized by vasodi-
lation. This is in notable contrast to the adaptive re-
sponse seen in rigid prosthetic grafts. We think that an
increase in wall shear induces atrophy of the neointima,
mediated through reduced cell replication and increased
cell death, because lumen diameter could not be in-
creased by vasodilation. Although the mechanisms of
atrophy have not been well characterized, we have hy-
pothesized that those mediators that regulate vascular
tone in intact arteries might also regulate flow-induced
remodeling of the graft neointima.35 We have previously
found an association between neointimal atrophy and
increased expression of endothelial NO synthase,8 and
this observation served as a basis for this investigation.
NO and flow-induced neointimal atrophy. In this
study, we showed that pharmacologic blockade of NO
production to the modest level achieved via systemic ad-
ministration of L-NAME did not affect the flow-mediated
reduction in neointimal cross-sectional area, SMC prolifer-
ation, or apoptosis. This observation seems contrary to the
perceived role of NO in vascular remodeling. Most research
has focused on the role of NO in the development of
neointimal hyperplasia and provided support for the con-
clusion that increasing NO production inhibits this pro-
cess.12,36,37 However, the role of NO in the vascular re-
modeling associated with increased flow, and more
Fig 2. BrdU (A) and TUNEL (B) staining within neointima of consecutive histologic sections. Note cell proliferation
located primarily in subendothelial region and cell death in neointima in deep juxtagraft region. Activated caspase-3
antibody staining (C) over neointimal cells adjacent to polytetrafluorethylene graft.
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specifically in flow-mediated neointimal regression, has not
been well defined. Several studies have confirmed the im-
portance of NO in mediating the early changes in lumen
diameter that occur in response to acute elevations in
flow.38,39 Yet to be clearly delineated is the importance of
NO in the remodeling process associated with chronic
increases in flow. Although some studies have suggested
that the structural remodeling in flow-loaded arteries is in
part NO dependent,19,40,41 other investigators have failed
to confirm this finding.42
Table IV. Effect of NOS inhibition on graft neointimal area and percentage of BrdU and TUNEL positive nuclei
L-NAME (n  6) D-NAME (n  5) ANOVA P values
Normal
flow High flow
Normal
flow High flow
Effect of
L-NAME
Effect of
flow
Neointimal area (mm2) 6.6  0.6 4.4  0.8 5.7  0.3 5.0  0.1 NS 	.001
BrdU labeling index (%) 3.7  1.5 2.9  1.0 4.6  1.3 2.7  0.6 NS .05
TUNEL labeling index (%) 4.1  1.5 4.5  1.4 3.3  1.0 5.7  2.1 NS NS
Values are mean  standard error of mean.
ANOVA, Analysis of variance; NS, not significant.
Table III. Hemodynamic changes in response to unilateral fistula placement: L-NAME and D-NAME treated animals
Before fistula After fistula
Control-
side graft
Fistula-side
graft
Control-
side graft
Fistula-side
graft
L-NAME Mean centerline velocity (cm/s) 37  9 38  9 20  3 123  16
L-NAME Shear stress (dynes/cm2) 26  6 27  6 14  2 86  11
D-NAME Mean centerline velocity (cm/s) 34  10 39  12 23  4 83  13
D-NAME Shear stress (dynes/cm2) 24  7 27  9 16  3 58  9
L-NAME: control-side graft, before versus after fistula, P  not significant. Fistula-side graft, before versus after fistula, P 	 .01.
D-NAME: Control-side graft, before versus after fistula, P  not significant. Fistula-side graft, before versus after fistula, P 	 .01.
Values are mean  standard error of mean.
Fig 3. SMC proliferation (BrdU labeling index; A), apoptosis (TUNEL labeling index; B), and nuclear density (C) in
neointima. Depth is measured from luminal surface and normalized to neointimal thickness. Values are mean 
standard error of mean.
BrdU staining: P  .005 (day 4) and P 	 .001 (day 14) for high versus normal flow.
TUNEL staining: P  .001 (day 4), P 	 .001 (day 7), and P 	 .001 (day 14) for high versus normal flow.
Nuclear density: P  .003 (day 7) and P 	 .001 (day 14) for high versus normal flow.
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Few investigators have performed both a physiologic
and pharmacologic evaluation after the administration of
NOS inhibitors; however, two recent manuscripts may
provide some insight into our findings. In a study by
Nishiyama et al,43 the effect of L-NAME, given as a 30-
mg/kg bolus and 50-mg/kg/h infusion, on renal hemo-
dynamics was evaluated. Administration of L-NAME re-
sulted in a 35% decrease in renal blood flow and a 24%
increase in renal artery pressure. These changes were asso-
ciated with a modest 16% reduction in cGMP levels within
the renal parenchyma. In an ex vivo experimental system,
Akiyama et al44 evaluated the impact of L-NAME on
endothelin-induced vasoconstriction and correlated their
finding to arterial cGMP levels. They found that treatment
of arterial segments in a bath of 0.3 mmol/L L-NAME
resulted in a significant inhibition in the contractile re-
sponse (averaging an approximate one-log inhibitory shift
in the dose response curve). This inhibition was associated
with a 30% reduction in cGMP levels.
Although our data suggest that flow-mediated graft
neointimal regression is not NO dependent, several addi-
tional explanations must be explored. The early time point
of this experiment was chosen to examine both the early
impact on cell kinetics and the later morphologic changes
in neointimal thickness. The negative findings in this study
may have related to the short duration of the treatment
period. Although significant reductions in platelet cGMP
and serum nitrate/nitrite levels were seen, we have not
documented pharmacologic blockade of NOS within the
graft neointima. Despite use of an L-NAME dose in this
experiment at the upper end of the range used by other
investigators,19-24 this dose may have been insufficient to
completely inhibit NO production. This potential concern
is also important in light of the relative sensitivity of the
various NOS isoforms to L-NAME. L-NAME is a more
selective inhibitor for the constitutive over the inducible
form of NOS,45 and insufficient blockade of an upregulated
iNOS may have yielded only partial blockade of NO pro-
duction. Other investigators have observed similar find-
ings.46
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